Tissue Regeneration Technologies to Be Issued New U.S. Patent Covering Its Softwave™ Technology8/24/2012
Woodstock, GA, August 24, 2012 -- TISSUE REGENERATION TECHNOLOGIES, LLC today announced that that the U.S. Patent and Trademark Office will issue the Company patent number 8257282 on September 4, 2012. The patent will cover an apparatus for generating pressure pulse/shock waves utilizing TRT’s unfocused, Softwave™ technology. The patent will comprise shock wave fronts having plane, nearly plane, convergent off target and/or divergent characteristics, and thus will embody a wide range of unfocused shock wave technologies and utilizations. John Warlick, CEO of TRT, described the patent issuance’s importance on the company’s ever-expanding intellectual property portfolio. “This latest patent is critically important to TRT and a milestone in that it will protect our unfocused shock wave – Softwave™ – franchise,” he said. “This broad patent for our unfocused technology for the treatment of tissue is invaluable in helping to develop and protect our Softwave™ technology.”
|
Specializing in sales of medical devices using our patented acoustic wave technology to profoundly accelerate healing and recoveries for the human body.
|
|
TRT's OrthoGold100 is FDA 501K cleared for the activation of connective tissue, the treatment of diabetic foot ulcers
& Registered for pain reduction and improved blood supply.
& Registered for pain reduction and improved blood supply.
© Copyright Tissue Regeneration Technologies | All Rights Reserved